BACKGROUND: Treatment for advanced lung adenocarcinoma (AC) has become increasingly personalized based on molecular results. However, for patients with AC brain metastases (BMs), intracranial outcomes based on molecular subtype and the frequency of molecular aberrations are less well defined. This study sought to report targeted next-generation sequencing results and investigate molecularly based outcomes for patients with AC-BMs treated with radiotherapy. METHODS: The records of 132 patients with AC-BMs treated at Emory University from September 2008 to August 2016 with successful next-generation sequencing were reviewed. Rates of local disease recurrence, distant brain failure (DBF), and salvage whole-brain radiotherapy (WBRT) were estimated using cumulative incidence with competing risk analysis. Univariate and multivariate analyses were performed. RESULTS: The most common aberrations included tumor protein 53 (TP53) (60%), KRAS (29%), epidermal growth factor receptor (EGFR) (20.5%), phosphatase and tensin homolog (PTEN) loss (15.5%), and MET amplification (13%). The majority of patients (62%) were treated with stereotactic radiosurgery alone. In these patients, KRAS mutation, anaplastic lymphoma kinase (ALK) rearrangement, and having ≥ 6 BMs were associated with an increased risk of salvage WBRT (P < .05). KRAS mutation remained significant for an increased risk of salvage WBRT when compared with EGFR/ALK/KRAS-negative patients (hazard ratio, 5.17; P < .05), despite a similar risk of DBF. PTEN loss was associated with increased risk of DBF (P < .05), whereas EGFR and ALK aberrations were associated with a decreased risk of local disease recurrence (P < .05). CONCLUSIONS: The results of the current study quantified the frequency of genetic aberrations in patients with AC-BMs and demonstrated their association with intracranial outcomes. In particular, a cohort of patients with KRAS mutations and ≥6 BMs were identified to be at high risk of requiring salvage WBRT after undergoing upfront stereotactic radiosurgery. Cancer 2018;124:3575-84.
INTRODUCTION
Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide and is responsible for nearly 40% of all brain metastases (BMs). 1 Historically, cytotoxic chemotherapy was considered as first-line systemic therapy for patients with advanced NSCLC, whereas intracranial disease was managed with radiotherapy (RT) and often surgical resection. The prognosis for patients with advanced NSCLC traditionally has been poor, with <15% surviving at 5 years. 2 More recently, the landscape for patients advanced NSCLC adenocarcinoma (AC) has shifted with the identification of oncogenic driver mutations. Targeted systemic therapies such as erlotinib 3, 4 and gefinitib 5 for epidermal growth factor receptor (EGFR) mutations as well as crizotinib 6 for anaplastic lymphoma kinase (ALK)-EML4 rearrangement have demonstrated improved disease-free survival compared with platinum-based doublet chemotherapy regimens such as cisplatin or carboplatin. In addition, mutations of Kirsten rat sarcoma viral oncogene homolog (KRAS) generally are mutually exclusive from EGFR and ALK aberrations, confer resistance to chemotherapy and EGFR-specific tyrosine kinase inhibitors (TKIs), 7 and likely represent a distinct subgroup of NSCLC-ACs. 8 Contemporary studies report that
Cancer September 1, 2018 the overall survival (OS) of patients with intracranial disease who have a targetable mutation and favorable clinical features (eg, good performance status) is approaching 4 years. 9 Testing for molecular markers has become standard of care and dictates first-line systemic therapies. 10 Currently, molecular mutations are not integrated into RT decision making for patients with intracranial disease. Given that there are distinct molecular subgroups with widely variable survival, a better understanding of intracranial outcomes based on these subgroups may be clinically relevant. In addition, to our knowledge no prior clinical studies have examined outcomes for patients with NSCLC BMs using next-generation sequencing (NGS), which limits the number of molecular aberrations examined.
In this context, the goal of the current study was to examine the frequency of molecular aberrations in patients with NSCLC-AC BMs who were treated at a multicenter academic institution using NGS and fluorescence in situ hybridization (FISH) analysis, and to identify molecular markers that may be associated with intracranial outcomes.
MATERIALS AND METHODS

Patient Selection
With approval of the institutional review board, the records of 143 consecutive patients with metastatic NSCLC-AC BMs who were treated with intracranial RT at Emory University Hospital, Emory University Hospital Midtown, and Emory St. Joseph's Hospital from September 2008 to August 2016 were reviewed retrospectively. Inclusion criteria included age ≥18 years, a pathologic diagnosis of lung AC, radiographic evidence of at least 1 BM, and successful testing via the TruSight 26 Cancer Mutation Panel (Illumina Inc, San Diego, California) or SNaPshot Multiplex Panel (Life Technologies, Grand Island, New York) as well as the FISH lung cancer panel. Exclusion criteria included any prior intracranial RT or the presence of leptomeningeal disease. Of the 143 patients, 132 met the inclusion criteria and were included in the current analysis. Although patients treated with upfront whole-brain RT (WBRT) were captured, they were excluded from analyses for local disease recurrence (LR) and the need for salvage WBRT. Separate analyses examining distant brain failure (DBF) were performed for all patients as well as those treated with stereotactic radiosurgery (SRS) alone.
Radiotherapy
Patients were treated with either WBRT with or without SRS boost or SRS alone as first intracranial RT. The decision regarding which upfront treatment method was used was made at the discretion of the treating physician and patient. Both linear accelerator (LINAC)-based SRS and Leskell Gamma Knife (Elekta AB, Stockholm, Sweden) SRS were used based on the treating facility. The prescribed dose was selected based on the Radiation Therapy Oncology Group 90-05 trial 11 and planning target volume margin as decided by the treating physician. WBRT was delivered using 3-dimensional conformal LINAC-based opposed lateral fields with multileaf collimation and the prescribed dose was selected by the treating physician.
Pathological Testing
TruSight Tumor 26 is an NGS platform capable of the parallel sequencing of short DNA fragments and is highly sensitive for the capture of low-frequency molecular variants; it has been described previously. 12 The SNaPshot Multiplex Panel is a multiplex polymerase chain reaction assay using single base primer excision and has been previously described. 13 Both panels have been validated previously at the study institution.
14 The specific mutations analyzed in the TruSight and SNaPshot panels are listed in Supporting Table 1 . The FISH lung cancer panel detects rearrangements of ALK at 2p23; ROS proto-oncogene 1 and receptor tyrosine kinase (ROS1) at 6q22; RET at 10q11.2; and gene amplification of MET using a ratio of MET to SE7 signals. Immunohistochemical staining also was performed for phosphatase and tensin homolog (PTEN) and cMET expression. As per institutional protocol, TruSight 26 testing was attempted first; if the sample failed quality control, SNaPshot testing was reflexively obtained.
Follow-Up and Assessment of Disease Progression
Follow-up with brain magnetic resonance imaging (MRI) occurred 4 to 6 weeks after SRS and 2 months to 3 months after WBRT. After the first follow-up, routine imaging occurred every 3 months thereafter unless clinically indicated sooner. DBF was defined as a new brain lesion detected on follow-up imaging that was not previously present during the upfront treatment. LR was defined as progression of a previously treated lesion with a ≥20% increase in the longest diameter as per the Response Evaluation Criteria in Solid Tumors (RECIST). 15 Cases for which imaging was equivocal
Cancer September 1, 2018 between LR and radiation necrosis were adjudicated through the consensus of a multidisciplinary brain tumor board. When deemed necessary, advanced techniques including MRI spectroscopy, MRI perfusion, and/or brain positron emission tomography as well as surgical resection were used to differentiate radiographic changes. Salvage WBRT was used for patients with DBF with diffuse BMs or a significant number of BMs that were not amenable to local therapy. This decision was left to the discretion of the treating physician and the patient.
Statistical Analysis
All statistical analyses were performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina Intracranial outcomes were calculated from the initiation of first intracranial RT to the event or competing risk, and OS was calculated from the start of first intracranial RT to death. LR, DBF, and salvage WBRT rates were estimated using cumulative incidence with competing risk analysis in which death without the event of interest was used as a competing risk. For LR and DBF, if patients did not experience the outcome or death, they were censored at the time of last brain imaging or salvage WBRT. For the analysis of LR and salvage WBRT, only those patients without upfront WBRT were included and patients without salvage WBRT or death were censored at the time of last brain imaging. DBF was examined for all patients as well as for patients treated with SRS alone. All variables were described using means with the standard deviation or frequency and percentages, as appropriate. OS was estimated using the Kaplan-Meier product-limit method. Univariate analysis (UVA), bivariate analysis, and multivariate analysis (MVA) were conducted using the method of Fine and Gray 17 for cumulative incidence endpoints and the Cox proportional hazards model for OS endpoints. MVA used a backwards variable selection method with an α ≥ .20 as removal criteria. A P value < .05 was considered to be statistically significant.
RESULTS
Patient and Tumor Characteristics
A total of 132 patients with 794 lesions were eligible for analysis. The median imaging follow-up was 10.6 months (range, 0-69.3 months Table 1 for complete patient and treatment characteristics. The relative frequency of genetic aberrations from NGS and FISH results are as follows: tumor protein 53 (TP53) mutation in 60.7% of patients, KRAS mutations in 28.9% of patients, EGFR mutations in 20.5% of patients, PTEN loss or sequence variation in 15.5% of patients, MET amplification in 13% of patients, adenomatous polyposis coli (APC) mutation in 8.5% of patients, STK11 mutation in 6.8% of patients, ALK rearrangement in 5.6% of patients, NRAS mutation in 5.1% of patients, PIK3CA mutation in 4.1% of patients, CTNNB1 mutation in 3.4% of patients, BRAF mutation in 3.1% of patients, FBXW7 mutation in 1.7% of patients, SMAD4 mutation in 1.7% of patients, RET rearrangement in 1.2% of patients, ROS translocation in 1.1% of patients, and MEK1 (MAP2K1) mutation in 1.0% of patients. No patients were identified as having aberrations in AKT1, CDH1, ERBB2/HER2, FDGFR2, FOXL2, GNAQ, GNAS, KIT, MSH6, PDGFRA, SRC, isocitrate dehydrogenase 1 (IDH1), or IDH2. Approximately 35.8% of patients had ≥ 2 mutations. Full molecular results are summarized in Fig. 1 .
Local Recurrence
For patients receiving upfront SRS alone (82 patients), the 6-month and 12-month cumulative incidence of LR was 1.4% (95% confidence interval [95% CI], 0.1%-6.9%) and 8.45% (95% CI, 3.1%-17.4%), respectively. The cumulative incidence of LR for patients with EGFR-mutant, ALKrearranged, KRAS-mutant, and WT BMs at 6 and 12
Cancer September 1, 2018 months was 0%, 0%, 5.8%, and 0%, respectively; and 0%, 0%, 13.2%, and 5.2%, respectively (Fig. 2) . On UVA, surgical resection (P = .041) and achieving a macroscopic total resection (P = .045) were associated with a reduced risk of LR. On bivariate analysis, BMs with EGFR and ALK aberrations were significant for a reduced risk of LR (P < .001) compared with WT BMs, whereas there was no significant difference noted between KRAS-mutated and WT BMs (hazard ratio [HR], 2.37; 95% CI, 0.5-12.0 [P = .298]). No other molecular aberrations were found to be significant for LR.
Distant Brain Failure
For all patients, the 6-month and 12-month cumulative incidence of DBF was 27.9% (95% CI, 20.3%-36.0%) and 39.4% (95% CI, 30.6%-48.1%), respectively. As expected, the receipt of upfront WBRT reduced the risk of DBF compared with receipt of upfront SRS alone (HR, 0.33; 95% CI, 0.2-0.6 [P < .001]). In addition, use of immunotherapy (HR, 1.99; 95% CI, 1.2-3.4 [P = .011]) and better Eastern Cooperative Oncology Group performance status (0-1 vs 2-4) (HR, 2.12; 95% CI, 1.0-4.4 [P = .04]) were found to be associated with an increased risk of DBF. No molecular aberrations were found to be significant for DBF in this cohort.
When excluding patients treated with upfront WBRT (82 patients), the 6-month and 12-month cumulative incidence of DBF was 41.2% (95% CI, 30.1%-52.0%) and 53.0% (95% CI, 40.8%-64.8%), respectively. The cumulative incidence of DBF for patients with EGFRmutant, ALK-rearranged, KRAS-mutant, and WT BMs at 6 and 12 months was 16.7% (95% CI, 2.4%-42.5%), 62.5% (95% CI, 0.1%-96.7%), 51.7% (95% CI, 28.0%-70.9%), and 39.8% (95% CI, 20.6%-58.5%), respectively; and 50.6% (95% CI, 14.7%-78.6%), not available, 62.6% (95% CI, 36.4%-80.4%), and 51.9% (95% CI, 30.3%-69.8%), respectively. On UVA, EGFR mutation trended toward a decreased risk of DBF (P = .17), whereas PTEN loss (P = .10), KRAS mutation (P = .13), and immunotherapy use (P = .06) trended toward an increased risk of DBF. On bivariate analysis comparing patients with KRAS-mutated with those with WT BMs, there was no significant increased risk of DBF noted (HR, 1.44; 95% CI, 0.71-2.92 [P = .308]) (Fig. 3A) . On MVA, PTEN loss (HR, 2.00; 95% CI, 1.06-3.77 [P = .032]) was found to be associated with an increased risk of DBF. In addition, KRAS mutation (HR, 1.85; 95% CI, 0.97-3.53 [P = .061]) and immunotherapy use (HR, 1.97; 95% CI, 1.0-3.9 [P = .051]) maintained strong trends for an increased risk of DBF (Table 2 ). Cancer September 1, 2018
Salvage WBRT
For patients receiving upfront SRS only (82 patients), the 6-month and 12-month cumulative incidence of salvage WBRT was 9.3% (95% CI, 4.0%-17.2%) and 18.5% (95% CI, 10.3%-28.5%), respectively. The 6-month and 12-month cumulative incidence of salvage WBRT for patients with EGFR-mutant, ALK-rearranged, KRAS-mutant, and WT BMs was 8.3% (95% CI, 0.4%-32.3%), 0% (95% CI, 0%-0%), 14.5% (95% CI, 3.4%-33.2%), and 4.0% (95% CI, 0.3%-17.5%), respectively; and 17.5% (95% CI, 2.4%-44.3%), 50% (95% CI, 0%-95.9%), 32.7% (95% CI, 12.5%-54.9%), and 8.3% (95% CI, 1.3%-23.7%), respectively. On UVA, ALK rearrangement (P = .002) and having ≥ 6 BMs (P = .015) were found to be statistically significant for an increased risk of salvage WBRT, while KRAS mutation maintained a strong trend (P = .065). On bivariate analysis comparing patients with KRAS-mutant to those with WT BMs, KRAS mutation was found to be significant for an increased risk of salvage WBRT (HR, 5.17; 95% CI, 1.07-24.9 [P = .04]) (Fig. 3B) 
Overall Survival
The median OS from the time of initiation of RT for the entire cohort was 11.5 months (range, 0.3-69.5 months). The median OS for patients with ALKrearranged, EGFR-mutant, KRAS-mutant, and WT BMs was 32.8 months (95% CI, 14.5 months to not reached), 17.1 months (95% CI, 12.8-52.7 months), 11.9 months (95% CI, 6.7-21. 
DISCUSSION
The growing molecular characterization of NSCLC-AC is an important advancement in precision medicine. Although current decisions regarding intracranial RT are not dictated by molecular results, improved stratification of intracranial outcomes and the need for salvage therapies based on molecular data are needed to inform patients and providers.
The results of the current study demonstrated several clinically relevant differences in intracranial Cancer September 1, 2018 outcomes based on molecular subtypes. In particular, to the best of our knowledge, this study is the first to report an increased risk of requiring salvage WBRT after upfront SRS for patients with a KRAS mutation. Given that the ultimate goal of upfront SRS is to avoid the detrimental neurocognitive toxicity of WBRT while controlling intracranial disease, the endpoint of salvage WBRT after upfront SRS is of particular clinical importance. When comparing patients with KRAS-mutations to those with WT disease, thereby removing EGFR-and ALK-targeted therapies as potential confounders on intracranial control, the association remained significant at 12 and 24 months. It is interesting to note that although the risk of DBF between KRAS-mutated and WT patients was not significant (HR, 1.44; 95% CI, 0.71-2.92 [P = .308]), KRAS-mutated patients developed more BMs and had Cancer September 1, 2018 a higher rate of requiring salvage WBRT than WT patients. This suggests that it is not the timing of intracranial failure but rather the disease burden at the time of DBF (eg, number of BMs and leptomeningeal disease) that affects this outcome. It also is important to note that OS was similar between KRAS-mutated and WT patients (HR, 1.00; 95% CI, 0.57-1.78 [P = .993]), indicating the observed difference in salvage WBRT was not a product of one subgroup being at risk of the event longer. These results emphasize the need for KRAS-specific targeted therapies. 18 Currently, the most promising drug class for this population appears to be inhibitors of the downstream effector MEK. While randomized trials to date have produced mixed results, 19, 20 this may be due to variable sensitivities of specific KRAS codon subtypes. 21 KRAS-specific therapies would be a major step forward and could have significant potential to augment intracranial control in this high-risk population.
Shin et al is currently the only study to examine salvage outcomes after SRS alone for patients with NSCLC BMs. 22 The authors reported that patients with EGFRmutated disease were more likely to undergo salvage therapies after disease recurrence (P = .04). 22 However, this result included salvage with SRS, WBRT, and/or surgery, with SRS constituting the majority of salvage treatments. While salvage SRS is commonly used for oligometastatic intracranial failure, salvage WBRT is generally reserved for diffuse intracranial disease progression and therefore is the more clinically relevant outcome. This finding also was likely confounded by the greater median survival of patients with EGFR-mutated disease, which could increase the likelihood of requiring salvage therapy in their analysis. Lastly, Shin et al did not examine the association between the number of BMs and salvage therapies, 22 for which the current study identified ≥6 BMs as being independently associated with an increased risk of requiring salvage WBRT. Cancer September 1, 2018
The presence of an ALK rearrangement was also found to be significant for requiring salvage WBRT after upfront SRS, but given the small number of patients with ALK-rearranged disease on MVA (4 patients), it is unclear how to interpret this result. Larger series have reported that despite higher rates of local control after SRS, this subgroup maintains high rates of intracranial failure and up to 40% of patients demonstrate intracranial disease progression at the time of death. 23 These outcomes are likely a result of the limited blood-brain barrier penetration of ALK-targeted therapies which allows the central nervous system to remain a sanctuary site. This pattern of failure suggests that patients with ALK-rearranged BMs should have close intracranial monitoring while receiving TKIs. New therapies such as the ALK inhibitor alectinib 24 have demonstrated improved blood-brain barrier penetration and represent a possible strategy with which to improve intracranial control.
For the outcome of DBF after upfront SRS, we demonstrated an increased risk for patients with PTEN loss. There are no prior reports of PTEN loss and an association with intracranial outcomes. PTEN is a known tumor suppressor gene in the phosphoinositide 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway, and decreased expression is associated with worse OS in patients with NSCLC. 25 It is interesting to note that BM samples have demonstrated an increased frequency of PI3K-Akt-mTOR alterations compared with primary tumor samples, indicating that this pathway may play a possible role in the development of metastatic subclones. 26 Loss of PTEN function also has been associated with downstream resistance mechanisms to EGFR-targeted therapy and therefore may contribute to intracranial resistance to systemic therapy despite adequate extracranial control. 27, 28 In the current study, only 4% of patients with PTEN aberrations had somatic mutations, suggesting that the predominant cause of reduced protein expression is likely downstream. It is interesting to note that PTEN loss was not found to be associated with an increased risk of salvage WBRT (P = .828) or OS (P = .083) in the current study cohort. In addition, immunotherapy use trended toward an increased risk of DBF (P = .061). This likely is a result of increased survival and thus the greater amount of time for which these patients are at risk to develop disease recurrence.
Prior studies have reported mixed rates of DBF for patients with EGFR, ALK, and KRAS mutations. 22, [29] [30] [31] [32] [33] [34] The majority of studies to date, however, included patients who received prior WBRT, which confounds the pattern of intracranial failure and makes the results difficult to interpret. Johung et al analyzed 81 patients with NSCLC-AC BMs, 32% of whom had received prior WBRT, and reported EGFR mutation status was not associated with an increased risk of DBF (P = .67). 31 Shin et al evaluated 96 patients with EGFR results who were treated with SRS alone and similarly demonstrated no difference in DBF based on EGFR status (P = .7) or receipt of targeted therapy. 22 Alternatively, Parikh et al examined 67 patients with EGFR and KRAS testing who were treated exclusively with SRS and reported an increased risk of DBF for patients with KRAS mutations (HR, 4.44; P = .004). 34 In the current analysis, after excluding patients with receipt of prior WBRT, the presence of KRAS and EGFR mutations trended toward an increased and decreased risk of DBF, respectively; however, neither ultimately was found to be statistically significant in the final MVA model. Further investigation into the prognostic significance of KRAS using a larger sample size is warranted. In addition, because third-generation EGFR-targeted TKIs such as osimertinib 35 have demonstrated improved blood-brain barrier penetration, future investigation into how these agents influence the pattern of intracranial failure is needed.
With regard to LR after SRS, we demonstrated a reduced risk for EGFR-mutated and ALK-rearranged BMs compared with WT BMs. Similar results have been reported by Johung et al 31 and Parikh et al (EGFR only), 34 indicating improved radiosensitivity for these subtypes when compared with KRAS or WT. Alternatively, Tomasini et al reported disease recurrences were less frequent in patients with KRAS mutations; however, comparisons with this study are difficult given that the treatments were highly heterogeneous (65 patients received either surgery, SRS, or WBRT), the type of disease recurrence (local vs distant) was not specified, and neither cumulative incidence nor competing risk analyses were used to account for the shorter survival of patients with KRAS mutations. 33 For OS, we corroborated several important prognostic factors. Both Mak et al 29 and Wang et al 30 demonstrated the receipt of EGFR-and ALK-targeted therapy to be associated with increased OS, whereas Parikh et al demonstrated similar correlation with EGFR positivity. 34 On UVA, the current study also identified receipt of targeted therapy to be statistically significant (P = .02); however, the presence of EGFR mutations and ALK rearrangement were maintained in preference to this variable on MVA. In addition, dsGPA, surgical resection, and use of immunotherapy were found to be significant for OS. The dsGPA incorporates age, performance status, presence of extracranial metastases, and number of BMs into a prognostic score. 16 Recently, the inclusion of EGFR and
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This study also demonstrated a wide range of molecular aberrations for patients with NSCLC-AC BMs based on targeted sequencing results. The most common include TP53 mutation, KRAS mutation, EGFR mutation, PTEN loss, MET amplification, APC mutation, and ALK rearrangement. The frequency of TP53 mutation (60%) reported herein was nearly twice the rate reported for NSCLC-AC from the COSMIC (Catalogue of Somatic Mutations in Cancer) database (32%), which is an online repository of somatic mutations in cancer. 36 KRAS mutation frequency also was higher in the current study population (28.9%) compared with the COSMIC database (18.7%). Preusser et al examined 76 resected NSCLC-AC BMs using NGS and found the most commonly identified mutated genes were TP53 (46.1%) and KRAS (38.2%). 37 The increased frequency of these 2 mutations in both 1) patients with known BMs and 2) primary BM tissue when compared with tumors of all stages contained in the COSMIC database suggests there may be a greater propensity for TP53-mutated and KRAS-mutated tumors to fail intracranially. Further investigation into which molecular aberrations confer the greatest risk of developing BMs is warranted.
A major consideration when interpreting the results of the current study is the potential phenotypic divergence that has been reported between primary tumor and BM samples. 26 The majority of tissue samples in this study were from primary tumors. Although this is an important caveat, the results maintain clinical relevance because the majority of sequencing in clinical practice is performed on primary tumor samples. However, sequencing of BM tissue should be considered when available to provide additional clinical data. Other limitations include the inherent bias of a retrospective analysis, moderate sample size, and the use of targeted sequencing, which only accounts for specific aberrations and has certain sensitivities and specificities. In addition, external validation of these results is warranted.
Strengths of this study include the report of clinically relevant intracranial outcomes including salvage therapies, use of a relatively homogenous population, use of modern sequencing techniques, detailed radiotherapy and systemic therapy use, and use of competing risk analyses.
The current study presents comprehensive sequencing results and summarizes modern intracranial outcomes based on molecular subtype for patients with NSCLC-AC BMs who were treated with RT. In particular, we identified patients with KRAS mutations and ≥6 BMs to be at high risk of requiring salvage WBRT after upfront SRS. Further investigation into the optimal management of this cohort is warranted. These results demonstrate that lung cancer molecular subtypes have the potential to guide RT decision making.
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